KalVista (KALV) Pharmaceuticals announced that its wholly-owned subsidiary, KalVista Pharmaceuticals, Ltd., has licensed commercialization rights in Japan to Kaken Pharmaceutical, for sebetralstat, an investigational, oral on-demand treatment for hereditary angioedema, or HAE. KalVista will receive an upfront payment of $11M, with an additional payment of up to $11M upon achievement of a regulatory milestone anticipated in early 2026. Beyond these payments, the Company is also eligible for commercial milestone payments, plus royalties based on the Japan National Health Insurance, or NHI, price, with the royalty rate as a percentage of sales approximately in the mid-twenties.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KALV:
- KalVista Pharmaceuticals’ Strategic Readiness and Market Potential Drive Buy Rating for Sebetralstat
- KalVista Pharmaceuticals: Promising Market Prospects for Sebetralstat with Imminent FDA Approval
- KalVista completes enrollment in KONFIDENT-KID clinical trial of sebetralstat
- Buy Rating for KalVista Pharmaceuticals Driven by Strategic Positioning and Market Potential of Sebetralstat
- Buy Rating for KalVista Pharmaceuticals: Strong Regulatory Progress and Market Potential for Sebetralstat